Free Trial
NASDAQ:CELZ

Creative Medical Technology (CELZ) Stock Price, News & Analysis

Creative Medical Technology logo
$2.70 +0.04 (+1.50%)
(As of 11/15/2024 ET)

About Creative Medical Technology Stock (NASDAQ:CELZ)

Key Stats

Today's Range
$2.61
$2.83
50-Day Range
$2.66
$5.35
52-Week Range
$2.52
$10.28
Volume
20,410 shs
Average Volume
69,842 shs
Market Capitalization
$4.73 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.

Creative Medical Technology Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
36th Percentile Overall Score

CELZ MarketRank™: 

Creative Medical Technology scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Creative Medical Technology.

  • Earnings Growth

    Earnings for Creative Medical Technology are expected to grow in the coming year, from ($3.19) to ($2.24) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Creative Medical Technology is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Creative Medical Technology is -0.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Creative Medical Technology has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Creative Medical Technology's valuation and earnings.
  • Percentage of Shares Shorted

    1.38% of the float of Creative Medical Technology has been sold short.
  • Short Interest Ratio / Days to Cover

    Creative Medical Technology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Creative Medical Technology has recently decreased by 20.61%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Creative Medical Technology does not currently pay a dividend.

  • Dividend Growth

    Creative Medical Technology does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.38% of the float of Creative Medical Technology has been sold short.
  • Short Interest Ratio / Days to Cover

    Creative Medical Technology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Creative Medical Technology has recently decreased by 20.61%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Creative Medical Technology has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Creative Medical Technology this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for CELZ on MarketBeat in the last 30 days.
  • MarketBeat Follows

    Only 1 people have added Creative Medical Technology to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Creative Medical Technology insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.80% of the stock of Creative Medical Technology is held by insiders.

  • Percentage Held by Institutions

    Only 1.42% of the stock of Creative Medical Technology is held by institutions.

  • Read more about Creative Medical Technology's insider trading history.
Receive CELZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Creative Medical Technology and its competitors with MarketBeat's FREE daily newsletter.

CELZ Stock News Headlines

Q1 Earnings Forecast for CELZ Issued By Roth Capital
📉 Warning: Market Crash Predicted - Secure Your Savings
The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.
See More Headlines

CELZ Stock Analysis - Frequently Asked Questions

Creative Medical Technology's stock was trading at $4.61 at the beginning of the year. Since then, CELZ shares have decreased by 41.4% and is now trading at $2.70.
View the best growth stocks for 2024 here
.

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) announced its earnings results on Friday, August, 9th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.27. The firm earned $0.01 million during the quarter.

Creative Medical Technology shares reverse split on the morning of Sunday, June 11th 2023. The 1-10 reverse split was announced on Sunday, June 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Sunday, June 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of CELZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Creative Medical Technology investors own include Sangamo Therapeutics (SGMO), Meta Platforms (META), FuelCell Energy (FCEL), Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL) and ChargePoint (CHPT).

Company Calendar

Last Earnings
8/09/2024
Today
11/17/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/28/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CELZ
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

Net Income
$-5,290,000.00
Pretax Margin
-48,354.54%

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$3.75 per share

Miscellaneous

Free Float
1,699,000
Market Cap
$4.73 million
Optionable
Not Optionable
Beta
2.01
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:CELZ) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners